Funding

Mark Lee Co-Founded N-Power Medicine Raises $32M in Series B Funding

Sep 2, 2026 | By Devin Jacobs

SUMMARY

Odyssey raised $74M in funding.
The funding will support market expansion.
Odyssey supports distributed renewable energy projects.

N-Power Medicine, a Redwood City, CA-based provider of an oncology drug development and community cancer patient care platform, has raised $32 million in a Series B funding round.

The round saw backers Labcorp Venture Fund, Merck Global Health Innovation Fund (Merck GHI), Innovatus Capital Partners, and others.

The company will use the capital to expand its community oncology research network, strengthen pharma partnerships, and advance its product development.

Funding Snapshot

Metric	Details
Fundraise Amount	$32M
Funding Round	Series B
Company	N-Power Medicine
Sector	HealthTech / Oncology
Headquarters	Redwood City, California, USA
Key Platform	ProECA

RECOMMENDED FOR YOU

Funding

[Funding alert] MA-based Inari Secures $103Million Funding

Devin Jacobs

Jan 31, 2024

Elevance Health to Acquire Paragon Healthcare

Devin Jacobs

Jan 5, 2024

Funding

[Funding alert] CA-based Topsort Secures $20Million in Series A Round Funding

Devin Jacobs

Mar 5, 2024

About N-Power Medicine

Founded in 2021 by Mark Lee, N-Power Medicine operates a national network of community oncology centers and provides an “always-on” Prospective External Control Arm (ProECA) platform for oncology drug developers. The platform aims to enable faster, smaller and more efficient clinical trials while expanding access to cancer research.

Core offerings include:

Prospective External Control Arms
Community oncology research
Clinical trial support
Oncology drug development

Core Technologies / Products / Services

Capability/Product	Application/Use Case
ProECA platform	Creates trial-grade external control arms
Community oncology network	Expands access to clinical research
NSCLC ProECA	Supports lung cancer drug development
Colorectal & prostate ProECA	Planned expansion into new cancer areas

Leadership Comments

“N-Power’s innovative approach has the potential to accelerate oncology drug development while expanding access to clinical research in community care settings,” said Megann Vaughn Watters, Managing Director, Labcorp Venture Fund.

“We’ve built a model that creates value for drug developers, community oncologists, and cancer patients. By bringing prospective external control arm programs directly into everyday cancer care, we dramatically speed up drug development while giving many more oncologists and patients access to research and innovative therapies,” said Mark Lee, M.D., Ph.D., N-Power Co-Founder and Chief Executive Officer.